ONCAlert | Upfront Therapy for mRCC

EGFR+ Lung Cancer VIEW MORE >>

Chemotherapy demonstrated superior progression-free survival to multiple EGFR tyrosine kinase inhibitors as first- or second-line treatment of patients with EGFR-mutant exon 20 non–small cell lung cancer. This finding is based on results from the largest real-world study of patients with EGFR exon 20 mutations conducted in China.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.